Table 1

Baseline characteristics of the study population (n = 11)
Variable
Clinical parameters
Male, n (%) 4 (36.4)
Age (yrs) 92.6 ± 1.3
BMI (kg/m2) 28.6 ± 3.0
Hypertension, n (%) 9 (81.8)
Dyslipidemia (%) 9 (81.8)
Smoker, n (%) 3 (27.3)
Diabetes mellitus, n (%) 7 (63.6)
Renal insufficiency (creatinine level > 1.5mg/dl), n (%) 6 (54.5)
Chronic hemodyalisis, n (%) 2 (18.2)
Chronic obstructive pulmonary disease, n (%) 2 (18.2)
New York Heart Association functional class (grade) 3.2 ± 0.8
Logistic EuroSCORE (%) 32.0 ± 9.5
STS score (%) 25.3 ± 9.7
Dyspnoe, n (%) 11 (100)
Angina, n (%) 4 (36.4)
Syncope, n (%) 4 (36.4)
Cardiac decompensation, n (%) 5 (45.5)
Pulmonal artery systolic pressure (mmHg) 40.8 ± 18.7
Porcelain aorta, n (%) 0 (0)
Ischemic heart disease, n (%) 8 (72.7)
Previous percutaneous coronary intervention, n (%) 6 (54.5)
Previous coronary artery bypass graft surgery, n (%) 4 (36.4)
Peripheral vessel disease, n (%) 2 (18.2)
Previous stroke, n (%) 2 (18.2)
Laboratory findings
Hemoglobin (mg/dl) 7.8 ± 1.2
Hematokrit (%) 37.7 ± 4.8
Creatinine (μmol/l) 183.9 ± 223.6
MDRD 48.2 ± 24.6
Medication
Aspirin 7 (63.6)
ACE-Inhibitor 7 (63.6)
ARB 2 (18.2)
Beta-Blocking agent 8 (72.7)
Ca-chanel blocker 3 (27.3)
Antiarythmic agent 0 (0)
Statin 7 (63.6)

Akin et al.

Akin et al. BMC Cardiovascular Disorders 2012 12:80   doi:10.1186/1471-2261-12-80

Open Data